Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN). Activation of TLR8 enhances natural killer cell activation, increases...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS One
Egile Nagusiak: Dietsch, Gregory N., Lu, Hailing, Yang, Yi, Morishima, Chihiro, Chow, Laura Q., Disis, Mary L., Hershberg, Robert M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2016
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771163/
https://ncbi.nlm.nih.gov/pubmed/26928328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0148764
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak